This is the Pulso Daily Briefing for October 22, 2026.

First, a profile. Pedro Gonzalez trained in physical medicine and rehabilitation, and now practices hormone optimization and functional medicine in Chicago. He came to hormone health through the patients who stalled in recovery, the ones whose sleep, mood, and hormones nobody had examined. His rule is diagnostic discipline before any prescription, and he is openly skeptical of his own field’s marketing.

Next, testosterone, tested. The trial record is narrower than the advertising. A diagnosis of deficiency takes symptoms plus two low morning measurements, and for men who meet that bar, therapy improves sexual function, corrects anemia, and supports bone density. The largest safety trial found no increase in major cardiac events, with more atrial fibrillation and pulmonary embolism in the treatment group. Monitoring is part of the therapy, not an extra.

Finally, the evidence on creatine after fifty. Paired with resistance training, creatine outperforms training alone on lean mass and some strength measures. Without training, it does very little. The dose used in most trials is three to five grams of creatine monohydrate daily, and loading phases are optional.

That is the briefing. Our promise stands: a better version of yourself, the more you read.